Sustainability & Climate

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

Whisker's Litter-Robot is now HSA/FSA eligible, a strategic move redefining medical expenses and giving it a major edge in the booming pet tech market.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Beyond the headlines of the G7 tech meeting in Montréal lies a blueprint for Canada's health future, impacting everything from AI diagnostics to local care.

Abaxx is launching UK wind futures, a critical financial tool to manage renewable energy volatility. Is this the key to de-risking the energy transition?

A new Regina clinic uses high-tech chairs to fight a silent health epidemic, blending innovation with a mission to break the billion-dollar taboo of incontinence.

Promising long-term data and key regulatory wins position Wugen's allogeneic therapy to disrupt the challenging T-cell cancer treatment landscape.

Immatics just secured $125M. This cash infusion is a major bet on its pioneering PRAME-targeted therapies and a key signal for the future of oncology.

Getlink's latest figures show a slowdown in cross-Channel traffic, revealing deep strains in the automotive sector and growing consumer caution.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

As Airbus doubles down in China, the partnership between Paris and Beijing reveals a pragmatic model balancing deep economic ties with a bold geopolitical vision.

A new program uses seismic waves and AI to map soil health at an unprecedented scale and cost, empowering a global movement to heal our planet's foundation.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.

Fresh off its investment-grade rating, the LatAm giant's oversubscribed bond issue signals a major power play. Here's how it plans to win the future.

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.

A new luxury A-frame in Missouri wine country did more than just build a rental; it invested $2M into local artisans, creating a new model for tourism.

Newmark poaches a top CBRE executive to lead its Occupier Solutions, aiming for a $2B revenue goal and challenging the industry's established giants.

Booking data reveals a shift in luxury travel towards privacy and curated experiences, forcing a supply chain evolution for those who cater to the elite.

An agency wins top awards for its storytelling, but the real prize is finding homes for 11,000 kids. Can narrative change the fate of a system in crisis?